Carcinoid tumors of the stomach
- PMID: 12946486
- DOI: 10.1016/s0960-7404(03)00034-3
Carcinoid tumors of the stomach
Abstract
Interest in gastric carcinoid tumors has in recent time amplified considerably as the understanding of both their biological background and clinical significance has developed. The increase in identification associated with the widespread availability of upper gastrointestinal endoscopy has facilitated diagnosis. In addition concern related to the consequences of long-standing hypergastrinemia generated by the use of potent acid-suppressive medications has augmented both clinical and scientific focus on gastric neuro endocrine issues. The elucidation of the regulatory mechanisms of the progenitor cell (ECL cell) of the gastric carcinoid tumor, the refinement of a pathological grading system for ECL cell proliferation, and the availability of specific immunohistologic identification techniques have further amplified the characterization of this lesion. Although the putative malignant potential of gastric carcinoids may ultimately be of only modest concern in a background of hypergastrinemia its relationship to gastric adenocarcinoma is still enigmatic and worthy of further consideration. This review will describe the molecular interrelationship between low-acid states, gastrin, and ECL cell proliferation and will discuss the pathological classification of the distinct types of gastric carcinoid tumors. In addition, the clinical rationale of current diagnostic and therapeutic strategies will be examined, providing a logical basis for the formulation of appropriate management strategies for patient care.
Similar articles
-
Gastric carcinoid tumors: the biology and therapy of an enigmatic and controversial lesion.Am J Gastroenterol. 1995 Mar;90(3):338-52. Am J Gastroenterol. 1995. PMID: 7872269 Review.
-
Gastric carcinoid.Curr Opin Oncol. 2005 Jan;17(1):1-6. doi: 10.1097/01.cco.0000147899.04701.c6. Curr Opin Oncol. 2005. PMID: 15608504 Review.
-
[Gastric carcinoid tumors].Rev Prat. 1997 Apr 15;47(8):863-7. Rev Prat. 1997. PMID: 9183965 Review. French.
-
Review of the pathogenesis, diagnosis, and management of type I gastric carcinoid tumor.World J Surg. 2011 Aug;35(8):1879-86. doi: 10.1007/s00268-011-1137-0. World J Surg. 2011. PMID: 21559999 Review.
-
Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids.Scand J Gastroenterol. 2011 Apr;46(4):456-63. doi: 10.3109/00365521.2010.539255. Epub 2010 Dec 7. Scand J Gastroenterol. 2011. PMID: 21133821
Cited by
-
Surgical treatment and prognosis of gastric neuroendocrine neoplasms: a single-center experience.BMC Gastroenterol. 2016 Sep 9;16(1):111. doi: 10.1186/s12876-016-0505-5. BMC Gastroenterol. 2016. PMID: 27613657 Free PMC article.
-
Duodenal neuroendocrine tumors: Impact of tumor size and total number of lymph nodes examined.J Surg Oncol. 2019 Dec;120(8):1302-1310. doi: 10.1002/jso.25753. Epub 2019 Nov 3. J Surg Oncol. 2019. PMID: 31680243 Free PMC article.
-
Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type.Ann Surg. 2005 Jul;242(1):64-73. doi: 10.1097/01.sla.0000167862.52309.7d. Ann Surg. 2005. PMID: 15973103 Free PMC article.
-
Long-term surgical outcomes of gastric neuroendocrine carcinoma and mixed neuroendocrine-non-neuroendocrine neoplasms.World J Surg Oncol. 2022 May 24;20(1):165. doi: 10.1186/s12957-022-02625-y. World J Surg Oncol. 2022. PMID: 35610656 Free PMC article.
-
Management and disease outcome of type I gastric neuroendocrine tumors: the Mount Sinai experience.Dig Dis Sci. 2015 Apr;60(4):996-1003. doi: 10.1007/s10620-014-3410-1. Epub 2014 Nov 16. Dig Dis Sci. 2015. PMID: 25399327
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical